By Drug Target Review2025-06-17T13:30:32
A new study at Science Tokyo has developed patient-derived organoids to better understand and combat resistance in oesophageal squamous cell carcinoma (ESCC).
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2023-04-12T15:28:08
Sponsored by nanoComposix
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2026-03-11T14:00:00
Sponsored by Merck
2024-01-09T09:30:19
Sponsored by Sartorius
2023-07-04T09:00:08
Sponsored by SB Drug Discovery
2024-02-01T11:52:50
Sponsored by Leica Microsystems
Site powered by Webvision Cloud